Zobrazeno 1 - 10
of 3 290
pro vyhledávání: '"adoptive cell therapy"'
Autor:
Cheng Zu, Wenxiao Li, Mingming Zhang, Yetian Dong, Shan Fu, Jingjing Feng, Ruimin Hong, He Huang, Yongxian Hu, Junwei Su
Publikováno v:
BMC Infectious Diseases, Vol 24, Iss 1, Pp 1-7 (2024)
Abstract Background Pneumocystis jirovecii pneumonia (PcP) is an opportunistic infection associated with immunocompromised patients. The development of novel immunotherapies has promoted the incidence of PcP. This study describes the clinical course
Externí odkaz:
https://doaj.org/article/396fe88399fc45c3b8ef0286d5d0d7d3
Publikováno v:
Journal of Ovarian Research, Vol 17, Iss 1, Pp 1-21 (2024)
Abstract Ovarian cancer, often referred to as the “silent killer,” is notoriously difficult to detect in its early stages, leading to a poor prognosis for many patients. Diagnosis is often delayed until the cancer has advanced, primarily due to i
Externí odkaz:
https://doaj.org/article/27ce0c22a5cb4ddc8eb5304d7b6146e5
Publikováno v:
Zhongguo linchuang yanjiu, Vol 37, Iss 9, Pp 1323-1326 (2024)
T cells are closely associated with tumor development and the homeostasis of the tumor microenvironment (TME). The co-receptors of immune checkpoints on the surface of T cells collectively regulate immune responses and can inhibit or kill tumor cells
Externí odkaz:
https://doaj.org/article/2e091915a6774037bb9282e43a85643f
Autor:
Chih-Hao Fang, Ya Fang Cheng, Shian-Ren Lin, Wan-Yu Lai, Li-Ren Liao, Yen-Ling Chiu, Jan-Mou Lee
Publikováno v:
BMC Cancer, Vol 24, Iss 1, Pp 1-11 (2024)
Abstract Background Lytic Epstein–Barr virus (EBV) infection plays a major role in the pathogenesis of nasopharyngeal carcinoma (NPC). For patients with recurrent or metastatic NPC and resistant to conventional therapies, adoptive cell therapy usin
Externí odkaz:
https://doaj.org/article/228dd9d1e6fe49869158254df1b7702b
Autor:
LIANG Yingyun, CHEN Jianhua
Publikováno v:
Zhongguo aizheng zazhi, Vol 34, Iss 7, Pp 686-694 (2024)
The oncolytic virus (OV) therapy utilizes natural or genetically modified viruses to specifically target and infect tumor cells, leading to the destruction of cancer cells by the replication of the virus itself. This process also alters the immune mi
Externí odkaz:
https://doaj.org/article/4dce059bc42148dc8a9cbf82796210e6
Publikováno v:
Journal of Hematology & Oncology, Vol 17, Iss 1, Pp 1-66 (2024)
Abstract Pancreatic cancer is a major cause of cancer-related death, but despondently, the outlook and prognosis for this resistant type of tumor have remained grim for a long time. Currently, it is extremely challenging to prevent or detect it early
Externí odkaz:
https://doaj.org/article/754012d6328b4b0cbf9d194a95e3cec0
Publikováno v:
JHEP Reports, Vol 6, Iss 10, Pp 101130- (2024)
Summary: Hepatocellular carcinoma (HCC) is a major global healthcare challenge, with >1 million patients predicted to be affected annually by 2025. In contrast to other cancers, both incidence and mortality rates continue to rise, and HCC is now the
Externí odkaz:
https://doaj.org/article/e509867026f1412fae200c7274ea9383
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
T cells engineered to express chimeric-antigen receptors (CAR-T cells) can effectively control relapsed and refractory haematological malignancies in the clinic. However, the successes of CAR-T cell therapy have not been recapitulated in solid tumour
Externí odkaz:
https://doaj.org/article/fa242560a31a4b1d922320b9532f4577
Autor:
Frontiers Production Office
Publikováno v:
Frontiers in Immunology, Vol 15 (2024)
Externí odkaz:
https://doaj.org/article/17d1236bbfba47deabb38b717d26442e
Autor:
Joanna Chmiel, Mariusz Stasiak, Maria Skrzypkowska, Lucjan Samson, Piotr Łuczkiewicz, Piotr Trzonkowski
Publikováno v:
Heliyon, Vol 10, Iss 17, Pp e36512- (2024)
Cellular therapies utilizing regulatory T cells (Tregs) have flourished in the autoimmunity space as a new pillar of medicine. These cells have shown a great promise in the treatment of such devastating conditions as type 1 diabetes mellitus (T1DM),
Externí odkaz:
https://doaj.org/article/719b97bd43d54ce881f54fde55f1c5b9